GLUE logo

Monte Rosa Therapeutics (GLUE) Company Overview

Profile

Full Name:

Monte Rosa Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 24, 2021

Indexes:

Not included

Website:

http://www.monterosatx.com

Description:

GLUE, a part of Monte Rosa Therapeutics, focuses on developing innovative therapies for cancer and other diseases. They use advanced technology to target and degrade specific proteins, aiming to create more effective treatments with fewer side effects, improving patient outcomes in the healthcare field.

Key Details

Price

$6.61

Market Cap

$406.10 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$2.63(-14.35% YoY)

PE Ratio

-

Annual ROE

-75.51%

Annual Debt To Equity

0.26

Beta

2.24

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 19, 24 Wells Fargo
Equal-Weight
Sep 12, 24 Wedbush
Outperform
Aug 12, 24 Wells Fargo
Overweight
Jun 28, 24 Piper Sandler
Overweight
May 22, 24 Wedbush
Outperform
Feb 15, 24 Wedbush
Outperform
Oct 19, 23 JP Morgan
Overweight
Aug 11, 23 Credit Suisse
Neutral
May 12, 23 Credit Suisse
Neutral
Mar 17, 23 Credit Suisse
Neutral

Screeners with GLUE included

Growing Shares Outstanding
US stocks
Stocks with high beta
Most recommended stocks
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks
Stocks above SMA 50

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$6.61
GLUE price is $6.61

Price All-time High

$42.21
GLUE price is currently -84.34% below its historical high of $42.21

Price Analysts Target

$15.00
GLUE price is currently -55.93% lower than the consensus analysts' forecast

Price Today Change

+5.09%
GLUE price is up +5.09% today

Price YTD Change

-4.76%
GLUE price is down -4.76% since January 1st

Price 3-Year Change

-54.26%
GLUE price is down -54.26% over the past 3 years

Market cap

Market Cap

$406.10 M
GLUE market capitalization is $406.10 million

Market Cap 3-Year Change

-39.61%
GLUE market capitalization is down -39.61% over the past 3 years

Market Cap All-time High

$1.96 B
GLUE market capitalization is currently -79.26% below its historical high of $1.96 billion

Market Cap Sector Rank

65.02%
GLUE market capitalization is higher than 65.02% of companies in Healthcare sector

Technical

Beta

2.24
GLUE beta is 2.24

200-day SMA

$5.93
GLUE price is currently +11.55% above its 200-day simple moving average

14-day RSI

52.41
GLUE 14-day relative strength index is 52.41

30-day Relative Volume

1.26
GLUE 30-day relative volume is 1.26

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
GLUE annual revenue value is unknown

Annual Revenue Analysts Estimate

$59.78 M
GLUE annual revenue is currently equal to the consensus analysts' forecast

Annual Revenue 1-Year Change

-
GLUE annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
GLUE annual revenue is unknown

Profit

Annual Gross Profit

-
GLUE annual gross profit value is unknown

Annual Gross Margin

-
GLUE annual gross profit margin value is unknown

Annual Operating Profit

-$143.31 M
GLUE annual operating income is -$143.31 million

Annual Operating Margin

-
GLUE annual operating profit margin value is unknown

Annual Net Income

-$135.35 M
GLUE annual net profit is -$135.35 million

Annual Net Margin

-
GLUE annual net profit margin value is unknown

EPS

Annual EPS

-$2.63
GLUE annual earnings per share is -$2.63

Annual EPS Analysts Estimate

-$1.11
GLUE annual earnings per share is currently +136.17% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

-14.35%
GLUE annual earnings per share is down -14.35% year-on-year

Annual EPS Sector Rank

36.17%
GLUE annual earnings per share is higher than 36.17% of companies in Healthcare sector

ROA & ROE

Annual ROA

-44.56%
GLUE annual return on assets is -44.56%

Annual ROE

-75.51%
GLUE annual return on equity is -75.51%

EBIT & EBITDA

Annual EBIT

-$143.31 M
GLUE annual earnings before interest & taxes is -$143.31 million

Annual EBITDA

-$137.09 M
GLUE annual EBITDA is -$137.09 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
GLUE price to earnings ratio value is unknown

PE Ratio Sector Rank

-
GLUE price to earnings ratio is unknown

PB Ratio

PB Ratio

1.98
GLUE price to book ratio is 1.98

PB Ratio Sector Rank

59.49%
GLUE price to book ratio is higher than 59.49% of companies in Healthcare sector

PS Ratio

PS Ratio

27.12
GLUE price to sales ratio is 27.12

PS Ratio Sector Rank

88.46%
GLUE price to sales ratio is higher than 88.46% of companies in Healthcare sector

Enterprise value

Enterprise Value

$324.22 M
GLUE enterprise value is $324.22 million

Enterprise Value Sector Rank

62.53%
GLUE enterprise value is higher than 62.53% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-2.68
GLUE EV/EBITDA is -2.68

EV/EBITDA Sector Rank

31.98%
GLUE EV/EBITDA is higher than 31.98% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

5.07
GLUE annual current ratio is 5.07

Annual Quick Ratio

-
GLUE annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.26
GLUE annual debt to equity ratio is 0.26

Annual Interest Coverage Ratio

-
GLUE annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
GLUE piotroski f-score value is unknown

Altman Z-Score

-
GLUE altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$303.75 M
GLUE annual total assets is $303.75 million

Annual Non Current Assets

$67.54 M
GLUE annual long term assets is $67.54 million

Annual Current Assets

$236.21 M
GLUE annual total current assets is $236.21 million

Annual Cash & Cash Equivalents

$128.10 M
GLUE annual cash & cash equivalents is $128.10 million

Equity

Annual Book Value

$179.25 M
GLUE annual book value is $179.25 million

Annual Working Capital

$189.62 M
GLUE annual working capital is $189.62 million

Liabilities

Annual Total Liabilities

$124.50 M
GLUE annual total liabilities is $124.50 million

Annual Total Long Term Liabilities

$77.91 M
GLUE annual total long term liabilities is $77.91 million

Annual Current Liabilities

$46.59 M
GLUE annual total current liabilities is $46.59 million

Annual Accounts Payable

$11.15 M
GLUE annual accounts payable is $11.15 million

Debt

Annual Total Debt

$46.04 M
GLUE annual total debt is $46.04 million

Annual Total Debt 1-Year Change

-2.05%
GLUE annual total debt is down -2.05% year-on-year

Annual Long Term Debt

$42.88 M
GLUE annual long term debt is $42.88 million

Annual Short Term Debt

$3.16 M
GLUE annual short term debt is $3.16 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$143.31 M
GLUE annual total expenses is $143.31 million

Annual Operating Expenses

$143.31 M
GLUE annual total operating expenses is $143.31 million

Annual Cost Of Goods Sold

-
GLUE annual cost of goods sold value is unknown

Annual SGA

$32.04 M
GLUE annual SGA is $32.04 million

Annual D&A

$6.22 M
GLUE annual depreciation & amortization is $6.22 million

Annual Interest Expense

-
GLUE annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$43.80 M
GLUE annual cash flow from operations is -$43.80 million

Annual CFO 1-Year Change

+52.63%
GLUE annual cash flow from operations is up +52.63% year-on-year

Annual CFI

$88.80 M
GLUE annual cash flow from investing activities is $88.80 million

Annual CFI 1-Year Change

+140.51%
GLUE annual cash flow from investing activities is up +140.51% year-on-year

Annual CFF

$27.49 M
GLUE annual cash flow from financing activities is $27.49 million

Annual CFF 1-Year Change

+34.33%
GLUE annual cash flow from financing activities is up +34.33% year-on-year

Free CashFlow

Annual FCF

-$62.84 M
GLUE annual free cash flow is -$62.84 million

Annual FCF 1-Year Change

+40.36%
GLUE annual free cash flow is up +40.36% year-on-year

CAPEX

Annual CAPEX

-
GLUE annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
GLUE annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

ANGO logo
AngioDynamics (ANGO)
PHAT logo
Phathom Pharmaceuticals (PHAT)
RVNC logo
Revance Therapeutics (RVNC)
MXCT logo
MaxCyte (MXCT)
HUMA logo
Humacyte (HUMA)
MRVI logo
Maravai LifeSciences Holdings (MRVI)
TRDA logo
Entrada Therapeutics (TRDA)
PACB logo
Pacific Biosciences of California (PACB)
STOK logo
Stoke Therapeutics (STOK)

FAQ

  • What is the ticker symbol for Monte Rosa Therapeutics?
  • Does Monte Rosa Therapeutics pay dividends?
  • What sector is Monte Rosa Therapeutics in?
  • What industry is Monte Rosa Therapeutics in?
  • What country is Monte Rosa Therapeutics based in?
  • When did Monte Rosa Therapeutics go public?
  • Is Monte Rosa Therapeutics in the S&P 500?
  • Is Monte Rosa Therapeutics in the NASDAQ 100?
  • Is Monte Rosa Therapeutics in the Dow Jones?
  • When was Monte Rosa Therapeutics's last earnings report?
  • When does Monte Rosa Therapeutics report earnings?
  • Should I buy Monte Rosa Therapeutics stock now?

What is the ticker symbol for Monte Rosa Therapeutics?

The ticker symbol for Monte Rosa Therapeutics is NASDAQ:GLUE

Does Monte Rosa Therapeutics pay dividends?

No, Monte Rosa Therapeutics does not pay dividends

What sector is Monte Rosa Therapeutics in?

Monte Rosa Therapeutics is in the Healthcare sector

What industry is Monte Rosa Therapeutics in?

Monte Rosa Therapeutics is in the Biotechnology industry

What country is Monte Rosa Therapeutics based in?

Monte Rosa Therapeutics is headquartered in United States

When did Monte Rosa Therapeutics go public?

Monte Rosa Therapeutics's initial public offering (IPO) was on June 24, 2021

Is Monte Rosa Therapeutics in the S&P 500?

No, Monte Rosa Therapeutics is not included in the S&P 500 index

Is Monte Rosa Therapeutics in the NASDAQ 100?

No, Monte Rosa Therapeutics is not included in the NASDAQ 100 index

Is Monte Rosa Therapeutics in the Dow Jones?

No, Monte Rosa Therapeutics is not included in the Dow Jones index

When was Monte Rosa Therapeutics's last earnings report?

Monte Rosa Therapeutics's most recent earnings report was on Nov 7, 2024

When does Monte Rosa Therapeutics report earnings?

The next expected earnings date for Monte Rosa Therapeutics is Mar 14, 2025

Should I buy Monte Rosa Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions